Cipla Limited (NSE: CIPLA)
India
· Delayed Price · Currency is INR | Market Cap | 1.18T |
| Revenue (ttm) | 262.64B |
| Net Income (ttm) | 44.75B |
| Shares Out | 807.60M |
| EPS (ttm) | 55.38 |
| PE Ratio | 26.46 |
| Forward PE | 24.93 |
| Dividend | 13.00 (0.88%) |
| Ex-Dividend Date | Aug 2, 2024 |
| Volume | 1,363,649 |
| Open | 1,470.00 |
| Previous Close | 1,471.55 |
| Day's Range | 1,453.85 - 1,478.10 |
| 52-Week Range | 1,164.55 - 1,702.05 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2024 |
About Cipla
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormaliti... [Read more]
Financial Performance
In 2023, Cipla's revenue was 255.37 billion, an increase of 13.20% compared to the previous year's 225.59 billion. Earnings were 41.22 billion, an increase of 47.10%.
Financial StatementsNews
Stock to Watch: Cipla faces USFDA observations at Bengaluru manufacturing unit
Cipla Ltd announced that the US Food and Drug Administration (USFDA) has issued eight observations following an inspection of its manufacturing facility in Virgonagar, Bengaluru. The inspection was co...
Cipla Share Price: Nomura upgrades Cipla to buy with 15% upside, sets target price at Rs 1,800
Nomura has upgraded Cipla to a “Buy” rating, establishing a target price of ₹1,800, reflecting a 15% potential upside from the current market price (CMP) of ₹1,560. The brokerage highlights Cipla’s fa...
Morning Gainers Today: Rainbow Children’s, Cipla, L&T, Anant Raj, and Kaynes Tech among top gainers as stocks rally
Here are some of the top gainers on the NSE this morning: Rainbow Children’s Medicare Ltd (RAINBOW) Price: ₹1,622.30 Change: +₹142.10 (+9.60%) Cipla Ltd (CIPLA) Price: ₹1,535.30 Change: +₹117.05 (+8.2...
Cipla hits upper circuit on open, rises 10% after strong Q2 results and mixed brokerage outlook
Cipla’s stock opened at ₹1,560.05 (10% UC) on the NSE and reached an early high of ₹1,560.05 before dipping to a low of ₹1,520.00. Currently trading at ₹1,529.30, the stock is up 7.83% from its previo...
Nifty 50 top losers today on 30 October: Cipla, Shriram Finance, SBI Life Insurance Company and more
The Nifty 50 benchmark index ended lower on Wednesday, driven by renewed selling from foreign portfolio investors (FPIs) and poor earnings reports from some of India’s blue-chip companies. The Nifty 5...
Morning Top Losers: Cipla, MCX India, Dixon Technologies, and more
Here’s a look at some of the top losers in the market this morning as stocks like Cipla, MCX India, and Dixon Technologies faced declines. Cipla led the losses with a drop of nearly 3.85% as of the la...
Stock to watch: Cipla drops 4.62% on weak Q2, brokerage reactions remain mixed
Cipla’s stock opened at ₹1,440.00, declining 4.62% from the previous close of ₹1,477.55, with a low of ₹1,407.20 so far today. Here’s a summary of brokerage reactions: Nomura: Maintained a Neutral rat...
Cipla Share Price: UBS maintains Buy, cuts target to Rs 1,960, sees 32.5% upside from current price
UBS has reiterated its Buy rating on Cipla, lowering the target price to ₹1,960 from ₹2,060, indicating a potential upside of 32.5% from the current market price of ₹1,479.00. Key insights from UBS’s ...
Cipla Share Price: Nomura maintains Neutral with target of Rs 1,568, sees 6% upside from current price
Nomura has maintained a Neutral rating on Cipla, setting a target price of ₹1,568, which implies a potential upside of 6% from the current market price of ₹1,479.00. Key insights from Nomura’s report:...
Cipla Share Price: Investec maintains Buy, reduces target to ₹1,800, expects 21.7% upside
Investec has reaffirmed a Buy rating on Cipla while lowering the target price to ₹1,800 from ₹1,900, suggesting a potential upside of 21.7% from the current market price of ₹1,479.00. Key insights fro...
Pharma Stocks Update: Check out how Cipla, Lupin, Abbott India, Divi’s Lab, Zydus Life, Dr Reddy’s Lab are performing today
JB Chem rises 1.91%, Biocon gains 0.87%, while Natco Pharma drops 2.65% and Gland Pharma slips 1.38% in today's trade.
Top Losers Today October 11, 204: TCS, M&M, and Cipla lead market declines amid volatility
On a challenging day for the markets, several major stocks ended in the red, with technology, auto, and pharma companies bearing the brunt of the decline. TCS, M&M, and Cipla emerged as the top losers...
Cipla stock dips 2% after brokerage downgrades
Cipla shares fell by 1.94%, trading at ₹1,587.50 at 9:18 AM today, following a brokerage downgrade. The drop was driven by a downgrade call from Nomura, which set a target price of ₹1,500, implying fu...
Citi on Cipla: Maintains Buy rating, expects 15.1% upside in share price
Citi has maintained its “Buy” rating on Cipla, with a target price of ₹1,870. With the current market price at ₹1,623.90, this implies an upside potential of approximately 15.1%. The brokerage noted t...
Top Losers on October 10: Cipla, Trent, Tech Mahindra, and more
Indian benchmark indices closed higher amid volatility on October 10, with the Nifty hovering around the 25,000 mark. The Sensex gained 144.31 points, or 0.18%, closing at 81,611.41, while the Nifty e...
Top Nifty Losers: Britannia down 1.37%, Cipla slips 1.28%, Adani Enterprises falls 1.15%, Trent declines 0.97%
As of 11:07 AM, several prominent stocks are facing declines in today’s session. Below are the top losers: Britannia dropped by 1.37%, trading at ₹6,013.90. Cipla declined by 1.28%, trading at ₹1,659....
Top Nifty Gainers Today: Cipla, Trent, Tata Motors, SBI, Maruti, Tech Mahindra lead the charge
The Nifty index witnessed some strong movements today with several stocks performing exceptionally well, led by Cipla, Trent, and Tata Motors among others. These stocks gained in value, contributing p...
Nifty Pharma hits record high, Divi’s Lab surges 5.83%, Cipla up 1.75%
he Nifty Pharma Index soared to record levels today, driven by strong performances across major pharmaceutical stocks. At 11:12 AM, Divi’s Laboratories led the rally, surging by 5.83%, followed by not...
Stocks hitting lower circuit today: Zee Media, PC Jeweller, Reliance Power and more
On October 4, multiple stocks hit their lower circuits amidst a flat trading session in the SE Midcap and Smallcap indices. Major losers on the Nifty included BPCL, Bajaj Finance, Cipla, NTPC, and Her...
Investec maintains Buy call on Cipla, sees 15% upside in share price
Investec has reiterated its Buy call on Cipla with a target price of ₹1,900, indicating a potential upside of 15% from the current price of ₹1,658.00. The brokerage remains optimistic about a 12-13% g...
JPMorgan maintains ‘Overweight’ on Cipla, expects 30% upside – Check out the target price
JPMorgan has maintained its ‘Overweight’ rating on Cipla, with a target price of ₹1,165, suggesting a potential upside of nearly 30% from the current price of ₹1,663.95. Cipla’s domestic growth outloo...
No stocks under F&O ban today; Bandhan Bank and RBL Bank close to limits
Indian benchmark indices ended lower on September 27, with the Nifty slipping below 26,200. The BSE Midcap and Smallcap indices remained relatively flat. The top losers on the Nifty included Power Gri...
Stocks to Watch: RIL, Adani Enterprises, BEL, GAIL, Kaynes Technology, Lupin, Jubilant Pharma, Zomato and morein focus today (Sept 30, 2024)
Indian benchmark indices ended lower on September 27, with the Nifty slipping below 26,200. The BSE Midcap and Smallcap indices remained relatively flat. The top losers on the Nifty included Power Gri...
Zydus, Cipla, Lupin, Divi’s: Pharma stocks surge after US House of Representatives passes Biosecure Act
Pharma stocks saw a significant uptick in early trading after the US House of Representatives passed the Biosecure Act, which aims to bolster the pharmaceutical supply chain and encourage domestic dru...
Cipla’s M K Hamied steps down as VC
Read about Cipla's M K Hamied stepping down as Vice-Chairman due to age and health reasons. His son Kamil Hamied appointed as non-executive director. Expert views on leadership continuity.